Key facts
- Tecregen’s last known valuation is $7.5M (Nov 2024).
- It has raised $15.4M; the latest was Seed Round ($12.6M) in Jan 2026.
- Notable investors include High-Tech Gründerfonds, Zürcher Kantonalbank, Boehringer Ingelheim Venture Fund, Boehringer Ingelheim, CARMA FUND Management — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Tecregen
- ·The full record, as it builds
Funding rounds
No funding rounds for Tecregen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tecregen
Operator of a biotechnology company intended to develop in-class therapies targeting thymus regeneration. The company is dedicated to advancing immuno-rejuvenation by developing next-generation therapies to regenerate the thymus, enabling healthcare providers to provide treatments and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2023
- Employees
- 10
- Website
- tecregen.com/
- Ownership
- Privately Held (backing)
Tecregen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tecregen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tecregen in its N-PORT filings yet. We sweep new filings monthly.